Biotech catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
- Completion LockedPhase 1/Phase 2NCT04068610COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRCMedImmune LLC · Metastatic Microsatellite-stable Colorectal CancerActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 10, 2022Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05039840Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus ErythematosusSanofi · Systemic Lupus ErythematosusActive, not recruitingSNYLead
- Enrollment
- Locked
- Primary completion
- Sep 4, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT07011706ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic DermatitisAclaris Therapeutics, Inc. · Atopic DermatitisActive, not recruitingACRSLead
- Enrollment
- Locked
- Primary completion
- Sep 21, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05831176A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic...Regeneron Pharmaceuticals · Eosinophilic Gastritis (EoG)Active, not recruitingREGNLeadSNYCollaborator
- Enrollment
- Locked
- Primary completion
- Feb 23, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03476681Study of NEO-201 in Solid Tumors Expansion CohortsPrecision Biologics, Inc · Non Small Cell Lung CancerActive, not recruitingDTILLead
- Enrollment
- Locked
- Primary completion
- Jun 17, 2026Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT03989414A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination...Celgene · Multiple MyelomaActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04999969Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or...AstraZeneca · Locally Advanced or Metastatic Solid TumoursActive, not recruitingAZNLead
- Enrollment
- Locked
- Primary completion
- Oct 7, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05094336A Study of Anvumetostat in Participants With Advanced MTAP-null Solid Tumors (MTAPESTRY 101)Amgen · Advanced MTAP-null Solid TumorsActive, not recruitingAMGNLead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05095727A Study of mRNA-3745 in Adult and Pediatric Participants With Glycogen Storage Disease Type 1a (GSD1a)ModernaTX, Inc. · Glycogen Storage DiseaseActive, not recruitingMRNALead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT05853575Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)Mirati Therapeutics Inc. · Advanced CancerActive, not recruitingBMYLead
- Enrollment
- Locked
- Primary completion
- Oct 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT06593522A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)Amgen · MTAP-deleted NSCLCActive, not recruitingAMGNLead
- Enrollment
- Locked
- Primary completion
- Oct 31, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT01594723A Study of LY2784544 in Participants With Myeloproliferative NeoplasmsEli Lilly and Company · Neoplasms, HematologicActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Mar 20, 2015Actual
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT02704858Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaNeonc Technologies, Inc. · Glioblastoma MultiformeActive, not recruitingNTHILead
- Enrollment
- Locked
- Primary completion
- Nov 30, 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT02711553A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract CancerEli Lilly and Company · Biliary Tract CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Feb 16, 2018Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT02768363Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)Candel Therapeutics, Inc. · Prostate CancerActive, not recruitingCADLLead
- Enrollment
- Locked
- Primary completion
- Nov 2024Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03604198Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeCorcept Therapeutics · Cushing SyndromeActive, not recruitingCORTLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT03706365A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate CancerEli Lilly and Company · Prostate CancerActive, not recruitingLLYLead
- Enrollment
- Locked
- Primary completion
- Jan 2, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT03964727Study of Sacituzumab Govitecan in Participants With Metastatic Solid TumorsGilead Sciences · Metastatic Solid TumorActive, not recruitingGILDLead
- Enrollment
- Locked
- Primary completion
- Jan 15, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT04442022A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse...Karyopharm Therapeutics Inc · Relapsed/Refractory Diffuse Large B-cell LymphomaActive, not recruitingKPTIQLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 2NCT04625270A Study of Avutometinib (VS-6766) v. Avutometinib (VS-6766) + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a...Verastem, Inc. · Low Grade Ovarian Serous AdenocarcinomaActive, not recruitingVSTMLead
- Enrollment
- Locked
- Primary completion
- Nov 15, 2024Actual
- Interventions
- Locked
- Completion LockedPhase 2/Phase 3NCT04871282A Study of AL102 in Patients With Progressing Desmoid TumorsImmunome, Inc. · DesmoidActive, not recruitingIMNMLead
- Enrollment
- Locked
- Primary completion
- Dec 3, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT04950075Study of INBRX-109 in Conventional ChondrosarcomaInhibrx Biosciences, Inc · Conventional ChondrosarcomaActive, not recruitingINBXLead
- Enrollment
- Locked
- Primary completion
- Sep 30, 2025Actual
- Interventions
- Locked
- Completion LockedPhase 2NCT05396885Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)Kite, A Gilead Company · Multiple MyelomaActive, not recruitingGILDLeadACLXCollaborator
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05664243A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination...In8bio Inc. · GlioblastomaActive, not recruitingINABLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
- Completion LockedPhase 1/Phase 2NCT05885464A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell...Beam Therapeutics Inc. · Lymphoblastic LymphomaActive, not recruitingBEAMLead
- Enrollment
- Locked
- Primary completion
- Dec 2026Sponsor estimate
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 74 more in this window; the full list is part of TrialScanner.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.